MetaCap

Champions Oncology (CSBR) vs OKYO Pharma (OKYO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Champions Oncology (CSBR) has outperformed OKYO Pharma (OKYO) over the past year, losing 35.9% versus a loss of 49.5%. Champions Oncology is the larger company by market cap ($60.4 million vs $56.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CSBR-35.89%OKYO-49.53%
+52%-1%-54%
Nov 21, 20251 yearNov 20, 2026
CSBR-36.27%OKYO-64.33%
+77%+1%-76%
May 16, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CSBR versus OKYO key metrics
MetricCSBROKYO
Share price$4.34$1.07
Market cap$60.41M$56.15M
1-day change-1.36%-7.76%
YTD return-37.19%-48.31%
1-year return-35.89%-49.53%
5-year return-52.98%—
Forward P/E43.40—
EPS (TTM)$-0.07$-0.24
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$59.42M—
Revenue growth (YoY)+4.36%—
Net income (latest FY)$-1.18M$-4.71M
Gross margin48.00%—
Operating margin-1.92%—
Net margin-1.98%—
52-week high$8.31$3.20
52-week low$4.34$1.00
Distance from 52-week high-47.77%-66.56%
Analyst consensus—strong_buy
Avg. price target upside—+678.50%
Average volume9.71K143.41K
Shares outstanding13.92M52.48M
Employees2145
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CSBR has outperformed OKYO by 13.6 percentage points over the past year.

About Champions Oncology

CSBR stock →

Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice through TumorGraft Technology Platform.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 214 employees

About OKYO Pharma

OKYO stock →

OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees

CSBR vs OKYO FAQ

Which is bigger, Champions Oncology or OKYO Pharma?

Champions Oncology (CSBR) is larger, with a market capitalization of $60.41M compared with $56.15M for OKYO Pharma (OKYO).

Which stock has performed better over the past year, CSBR or OKYO?

CSBR returned -35.89% over the past 12 months, compared with -49.53% for OKYO (price return, excluding dividends). Past performance does not predict future results.

Are Champions Oncology and OKYO Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons